Intellia Therapeutics to Present at September Healthcare Investor Conferences
31 Août 2021 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing curative therapeutics
using CRISPR/Cas9 technology both in vivo and ex vivo, will present
at the following virtual healthcare investor conferences in
September:
Thursday, September 9, 2021Wells Fargo
Healthcare ConferenceTime: 10:40 am ET
Monday, September 13, 2021H.C.
Wainwright 23rd Annual Global
Investment ConferenceTime: 7:00 am ET
A live webcast of Intellia’s presentations at these events will
be accessible through the Events and Presentations page of the
Investor Relations section of the company’s website
at www.intelliatx.com. To access the webcasts, please log on
to the Intellia website approximately 15 minutes prior to the start
time to ensure adequate time for any software downloads that may be
required. A replay of the webcasts will be available on Intellia’s
website for approximately 14 days following each presentation.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics using
CRISPR/Cas9 technology. To fully realize the transformative
potential of CRISPR/Cas9, Intellia is pursuing two primary
approaches. The company’s in vivo programs use intravenously
administered CRISPR as the therapy, in which proprietary delivery
technology enables highly precise editing of disease-causing genes
directly within specific target tissues. Intellia’s ex vivo
programs use CRISPR to create the therapy by using engineered human
cells to treat cancer and autoimmune diseases. Intellia’s deep
scientific, technical and clinical development experience, along
with its robust intellectual property portfolio, have enabled the
company to take a leadership role in harnessing the full potential
of CRISPR/Cas9 to create new classes of genetic medicine. Learn
more at intelliatx.com. Follow us on
Twitter @intelliatweets.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024